Celltrion announced on Friday that it will immediately implement the newly eased US biosimilar development rules across its pipeline. This strategic move is projected to significantly reduce development costs and accelerate timelines.
This decision comes in response to the recent release of the fourth revision of the biosimilar development Q&A guidelines by the US Food and Drug Administration (FDA). These updated guidelines simplify the requirements for pharmacokinetic (PK) testing of biosimilars.
A key modification within the revision involves a relaxation of the criteria for reference drugs utilized in clinical comparisons. Previously, companies seeking market entry in the US were obligated to conduct pharmacokinetic comparative trials using US-approved reference drugs. Under the revised guidelines, comparisons using non-US reference drugs will now also be accepted, broadening the scope of acceptable clinical data.
Celltrion anticipates that this change will potentially reduce overall clinical development costs by up to 25 percent, especially in therapeutic areas like immuno-oncology, where reference drugs are notably expensive. This cost reduction offers significant advantages in bringing affordable biosimilars to market.
The company further stated that the regulatory streamlining will enable them to expedite development processes and more efficiently allocate resources across their extensive pipeline. This acceleration is critical for quickly responding to market needs.
With its fully integrated structure, encompassing drug development, manufacturing, and direct global sales capabilities, Celltrion intends to reinvest the resulting cost savings into expanding its biosimilar portfolio. This expansion will include products targeting smaller and mid-sized markets, enhancing global accessibility to vital medications.
Celltrion currently markets 11 biosimilar products and has ambitious plans to expand its portfolio to a total of 41 products by 2038. This robust growth strategy emphasizes the company’s commitment to the biosimilar market.
The company estimates that the combined market size for these 41 products could exceed 400 trillion won ($296 billion), representing a significant increase compared to the 85 trillion won market targeted by its existing products last year. This expansion indicates substantial future growth potential.
“This global regulatory easing presents a major opportunity for us to reduce development costs and accelerate pipeline expansion,” stated a company official. They further highlighted Celltrion’s existing capabilities in early-stage development, large-scale manufacturing, and direct sales as key drivers for capitalizing on these opportunities.
stlee0329
